Everolimus is an active agent in medullary thyroid cancer: A clinical and in vitro study

A. Faggiano, V. Ramundo, A. Dicitore, S. Castiglioni, M. O. Borghi, R. Severino, P. Ferolla, L. Crinò, A. Abbruzzese, P. Sperlongano, M. Caraglia, D. Ferone, L. Hofland, A. Colao, G. Vitale

Research output: Contribution to journalArticle

Abstract

Everolimus, an mTOR inhibitor, which has been demonstrated to induce anti-tumour effects in different types of neuroendocrine tumours, has never been evaluated in patients with medullary thyroid cancer (MTC). The aim of this study was to evaluate the in vitro and in vivo effects of everolimus in combination with octreotide in MTC. Two patients with progressive metastatic MTC and high calcitonin levels were treated with everolimus 5-10 mg/day. Both patients were under treatment with octreotide LAR at the study entry. An in vitro study was also performed to assess everolimus effects on MTC cell lines (TT and MZ-CRC-1 cells). A tumour response was observed in both patients. Serum calcitonin decreased by 86% in patient 1 and by 42% in patient 2. In TT and MZ-CRC-1 cells, everolimus induced a significant dose-dependent inhibition in cell proliferation. This effect seems to be related to a cell cycle arrest in G0/G1 phase in both cell lines and to the induction of cellular senescence in TT cells. Everolimus in combination with octreotide may be active as anti-tumour therapy in patients with progressive metastatic MTC, suggesting to further evaluate this agent in MTC patients in a large prospective study.

Original languageEnglish
Pages (from-to)1563-1572
Number of pages10
JournalJournal of Cellular and Molecular Medicine
Volume16
Issue number7
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Octreotide
Calcitonin
Cell Line
Neoplasms
Cell Cycle Resting Phase
Neuroendocrine Tumors
Everolimus
In Vitro Techniques
Medullary Thyroid cancer
Cell Aging
G1 Phase
Cell Cycle Checkpoints
Cell Proliferation
Prospective Studies
Therapeutics
Serum

Keywords

  • Calcitonin
  • Everolimus
  • Medullary thyroid cancer
  • Neuroendocrine tumour
  • Somatostatin analogues

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine

Cite this

Everolimus is an active agent in medullary thyroid cancer : A clinical and in vitro study. / Faggiano, A.; Ramundo, V.; Dicitore, A.; Castiglioni, S.; Borghi, M. O.; Severino, R.; Ferolla, P.; Crinò, L.; Abbruzzese, A.; Sperlongano, P.; Caraglia, M.; Ferone, D.; Hofland, L.; Colao, A.; Vitale, G.

In: Journal of Cellular and Molecular Medicine, Vol. 16, No. 7, 07.2012, p. 1563-1572.

Research output: Contribution to journalArticle

Faggiano, A, Ramundo, V, Dicitore, A, Castiglioni, S, Borghi, MO, Severino, R, Ferolla, P, Crinò, L, Abbruzzese, A, Sperlongano, P, Caraglia, M, Ferone, D, Hofland, L, Colao, A & Vitale, G 2012, 'Everolimus is an active agent in medullary thyroid cancer: A clinical and in vitro study', Journal of Cellular and Molecular Medicine, vol. 16, no. 7, pp. 1563-1572. https://doi.org/10.1111/j.1582-4934.2011.01438.x
Faggiano, A. ; Ramundo, V. ; Dicitore, A. ; Castiglioni, S. ; Borghi, M. O. ; Severino, R. ; Ferolla, P. ; Crinò, L. ; Abbruzzese, A. ; Sperlongano, P. ; Caraglia, M. ; Ferone, D. ; Hofland, L. ; Colao, A. ; Vitale, G. / Everolimus is an active agent in medullary thyroid cancer : A clinical and in vitro study. In: Journal of Cellular and Molecular Medicine. 2012 ; Vol. 16, No. 7. pp. 1563-1572.
@article{c25ffb3c67cb4a9c9a2fdedec2e4b3d9,
title = "Everolimus is an active agent in medullary thyroid cancer: A clinical and in vitro study",
abstract = "Everolimus, an mTOR inhibitor, which has been demonstrated to induce anti-tumour effects in different types of neuroendocrine tumours, has never been evaluated in patients with medullary thyroid cancer (MTC). The aim of this study was to evaluate the in vitro and in vivo effects of everolimus in combination with octreotide in MTC. Two patients with progressive metastatic MTC and high calcitonin levels were treated with everolimus 5-10 mg/day. Both patients were under treatment with octreotide LAR at the study entry. An in vitro study was also performed to assess everolimus effects on MTC cell lines (TT and MZ-CRC-1 cells). A tumour response was observed in both patients. Serum calcitonin decreased by 86{\%} in patient 1 and by 42{\%} in patient 2. In TT and MZ-CRC-1 cells, everolimus induced a significant dose-dependent inhibition in cell proliferation. This effect seems to be related to a cell cycle arrest in G0/G1 phase in both cell lines and to the induction of cellular senescence in TT cells. Everolimus in combination with octreotide may be active as anti-tumour therapy in patients with progressive metastatic MTC, suggesting to further evaluate this agent in MTC patients in a large prospective study.",
keywords = "Calcitonin, Everolimus, Medullary thyroid cancer, Neuroendocrine tumour, Somatostatin analogues",
author = "A. Faggiano and V. Ramundo and A. Dicitore and S. Castiglioni and Borghi, {M. O.} and R. Severino and P. Ferolla and L. Crin{\`o} and A. Abbruzzese and P. Sperlongano and M. Caraglia and D. Ferone and L. Hofland and A. Colao and G. Vitale",
year = "2012",
month = "7",
doi = "10.1111/j.1582-4934.2011.01438.x",
language = "English",
volume = "16",
pages = "1563--1572",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Everolimus is an active agent in medullary thyroid cancer

T2 - A clinical and in vitro study

AU - Faggiano, A.

AU - Ramundo, V.

AU - Dicitore, A.

AU - Castiglioni, S.

AU - Borghi, M. O.

AU - Severino, R.

AU - Ferolla, P.

AU - Crinò, L.

AU - Abbruzzese, A.

AU - Sperlongano, P.

AU - Caraglia, M.

AU - Ferone, D.

AU - Hofland, L.

AU - Colao, A.

AU - Vitale, G.

PY - 2012/7

Y1 - 2012/7

N2 - Everolimus, an mTOR inhibitor, which has been demonstrated to induce anti-tumour effects in different types of neuroendocrine tumours, has never been evaluated in patients with medullary thyroid cancer (MTC). The aim of this study was to evaluate the in vitro and in vivo effects of everolimus in combination with octreotide in MTC. Two patients with progressive metastatic MTC and high calcitonin levels were treated with everolimus 5-10 mg/day. Both patients were under treatment with octreotide LAR at the study entry. An in vitro study was also performed to assess everolimus effects on MTC cell lines (TT and MZ-CRC-1 cells). A tumour response was observed in both patients. Serum calcitonin decreased by 86% in patient 1 and by 42% in patient 2. In TT and MZ-CRC-1 cells, everolimus induced a significant dose-dependent inhibition in cell proliferation. This effect seems to be related to a cell cycle arrest in G0/G1 phase in both cell lines and to the induction of cellular senescence in TT cells. Everolimus in combination with octreotide may be active as anti-tumour therapy in patients with progressive metastatic MTC, suggesting to further evaluate this agent in MTC patients in a large prospective study.

AB - Everolimus, an mTOR inhibitor, which has been demonstrated to induce anti-tumour effects in different types of neuroendocrine tumours, has never been evaluated in patients with medullary thyroid cancer (MTC). The aim of this study was to evaluate the in vitro and in vivo effects of everolimus in combination with octreotide in MTC. Two patients with progressive metastatic MTC and high calcitonin levels were treated with everolimus 5-10 mg/day. Both patients were under treatment with octreotide LAR at the study entry. An in vitro study was also performed to assess everolimus effects on MTC cell lines (TT and MZ-CRC-1 cells). A tumour response was observed in both patients. Serum calcitonin decreased by 86% in patient 1 and by 42% in patient 2. In TT and MZ-CRC-1 cells, everolimus induced a significant dose-dependent inhibition in cell proliferation. This effect seems to be related to a cell cycle arrest in G0/G1 phase in both cell lines and to the induction of cellular senescence in TT cells. Everolimus in combination with octreotide may be active as anti-tumour therapy in patients with progressive metastatic MTC, suggesting to further evaluate this agent in MTC patients in a large prospective study.

KW - Calcitonin

KW - Everolimus

KW - Medullary thyroid cancer

KW - Neuroendocrine tumour

KW - Somatostatin analogues

UR - http://www.scopus.com/inward/record.url?scp=84863095977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863095977&partnerID=8YFLogxK

U2 - 10.1111/j.1582-4934.2011.01438.x

DO - 10.1111/j.1582-4934.2011.01438.x

M3 - Article

C2 - 21883896

AN - SCOPUS:84863095977

VL - 16

SP - 1563

EP - 1572

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 7

ER -